Samsung Biologics Q2 Sales Reach KRW 1.2899 Trillion... Surpasses KRW 2 Trillion in First-Half Sales for the First Time

Annual Sales Growth Forecast Raised to 25-30%

On July 23, Samsung Biologics announced that its consolidated sales for the second quarter of this year reached KRW 1.2899 trillion, an increase of KRW 133 billion compared to the same period last year. Operating profit was KRW 475.6 billion, up KRW 41.1 billion year-on-year.

Aerial view of Samsung Biologics in Yeonsu-gu, Incheon. Samsung Biologics

As a result, consolidated sales for the first half of 2025 amounted to KRW 2.5882 trillion, with operating profit at KRW 962.3 billion. Compared to the same period last year, sales increased by KRW 484.4 billion and operating profit by KRW 306.5 billion.

On the same day, Samsung Biologics announced through a fair disclosure that it has raised its annual consolidated sales growth forecast for this year from the previous 20-25% to 25-30%. This adjustment is attributed to improved operational efficiency at Plants 1-3, as well as the ramp-up (expanded operation) of Plant 4.

Samsung Biologics Surpasses KRW 2 Trillion in Standalone Sales for the First Half

Samsung Biologics

For the first time since its founding, Samsung Biologics surpassed KRW 2 trillion in standalone sales for the first half of the year. Standalone sales for the first half reached KRW 2.0138 trillion, and operating profit was KRW 907.1 billion. These figures represent increases of KRW 534.1 billion and KRW 345.1 billion, respectively, compared to the same period last year.

Standalone sales for the second quarter were KRW 1.0142 trillion, and operating profit was KRW 477 billion, up KRW 204 billion and KRW 147.8 billion, respectively, year-on-year. This was driven by the stable full operation of Plants 1-3 and the 60,000-liter facility at Plant 4, which began partial operation in October 2022, as well as the early ramp-up of the 180,000-liter facility at Plant 4.

Samsung Biologics continues to show a clear upward trend in order growth in 2025. Starting with a record-breaking contract worth over KRW 2 trillion signed in January, the company has secured a series of large-scale contracts with global pharmaceutical companies, achieving more than 60% of the previous year’s total annual order value in just the first half. Since its founding, the cumulative total order value has reached approximately USD 18.7 billion.

The company is also strengthening its competitiveness in the global contract development and manufacturing organization (CDMO) market. In May, Samsung Biologics announced a plan to completely separate its biopharmaceutical CDMO business and biosimilar business through a spin-off. Through this separation, the company aims to establish its identity as a pure-play CDMO, further solidifying trust and partnerships with clients. In addition, the independent evaluation of the two businesses, each with distinct characteristics, is expected to have a positive effect on shareholder value.

With global demand for CDMO services increasing, Samsung Biologics is also expanding its production capacity. In April, the company began full-scale operation of Plant 5, a 180,000-liter facility that leverages automation and digitalization to enhance operational efficiency and quality standards. As a result, Samsung Biologics now has a total production capacity of 784,000 liters and plans to add three more plants to its Second Bio Campus by 2032, aiming for a total capacity of 1,324,000 liters to secure an 'ultra-gap' in manufacturing scale.

Investments to expand the company’s portfolio are also ongoing. To enter the clinical research organization (CRO) service sector, Samsung Biologics launched the 'Samsung Organoid' service. Through this, the company plans to collaborate with clients from the early stages of drug candidate discovery, achieving early lock-in and building long-term partnerships. Furthermore, the company is diversifying its modalities (therapeutic approaches) by leveraging advanced technologies such as antibody-drug conjugates (ADC), multi-specific antibodies, and adeno-associated virus (AAV) gene therapies.

The company is also actively expanding its global presence to strengthen its order base. In addition to its existing offices in New Jersey and Boston, Samsung Biologics opened a new sales office in Tokyo, Japan, earlier this year, broadening its reach to clients in Asia. Based on its CDMO competitiveness, Samsung Biologics plans to further strengthen its order activities targeting the global top 40 pharmaceutical companies.

Samsung Bioepis: Second Quarter Sales of KRW 401 Billion, Operating Profit of KRW 89.8 Billion

Samsung Bioepis

Samsung Bioepis reported second quarter sales of KRW 401 billion and operating profit of KRW 89.8 billion. These figures represent decreases of KRW 128.9 billion and KRW 167.3 billion, respectively, compared to the same period last year. This decline is due to the recognition of KRW 220.5 billion in milestone revenue (compensation for R&D achievements) in the second quarter of last year. Excluding milestone revenue, sales increased by 28% year-on-year.

Samsung Bioepis continues to demonstrate steady growth through expanding product sales. In particular, sales are being driven by its base in Europe, where eight products are sold, and by two new products (Stelara and Soliris biosimilars) launched in the U.S. market in partnership with global pharmaceutical companies Sandoz and Teva during the first half. Growth is expected to continue in the second half, especially with the full-scale supply of the Stelara biosimilar in the U.S. market.

In June, the company also accelerated its global expansion by signing a partnership agreement with Japanese pharmaceutical distributor Nipro to enter the Japanese market and a partnership with ophthalmology specialist Harrow to sell ophthalmic disease treatments in the U.S.

In Korea, Samsung Bioepis launched the Prolia biosimilar 'Obodense' at a price approximately 13% lower than the original drug. With this, the company has launched a total of 10 biosimilars in Korea over the past 10 years, through direct sales and collaborations with specialized distributors, covering the fields of immunology, oncology, ophthalmology, hematology and nephrology, and endocrinology.

This content was produced with the assistance of AI translation services.